Bloomberg Intelligence
Rx Savings' Rea on Mylan Under Scrutiny for EpiPen Price(Audio)
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Michael Rea, CEO of Rx Savings Solutions, to discuss Mylan's EpiPen price hike, currently under scrutiny.
See omnystudio.com/listener for privacy information.